Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads following the announcement of a strategic partnership with US-based Long Grove Pharmaceuticals.

The article outlines how the partnership will help accelerate Optiscan’s entry into the US clinical market by leveraging Long Grove’s deep expertise in regulatory, reimbursement, and commercialisation strategy.

The collaboration is a key milestone in Optiscan’s push towards FDA clearance and clinical use of its real-time, slide-free imaging technology.

“It provides further evidence that more and more healthcare sector-related groups are wanting to partner with Optiscan’s technology, as they search for ways to enhance and/or expand usage of their own product offerings," Dr. Camile Farah, Optiscan CEO.

Stockhead – Read the full article here.
The Australian – Read the full article here.